What happens when you stop taking Mounjaro or Wegovy?

If you're taking Mounjaro (tirzepatide) or Wegovy (semaglutide) for weight loss, it's worth understanding what tends to happen if you stop, whether that's because a course has come to a natural end, because of cost, or because you and your prescriber have decided it's the right time to come off treatment.

This guide covers why appetite usually returns after stopping, what trial evidence shows about weight regain, the wider health effects that can come with it, the support NICE recommends, and the options available if stopping completely isn't the only path.

Why appetite tends to come back after stopping

Mounjaro and Wegovy belong to a class of medicines that act on GLP-1 (and, for Mounjaro, GIP) receptors involved in appetite regulation. While you're taking them, they reduce hunger, increase the feeling of fullness after eating, and for many people quieten the near-constant thoughts about food sometimes called "food noise."

That effect depends on the medicine being in your system at an active dose. Once you stop, the drug is gradually cleared from your body over roughly the following month, and as levels fall, the appetite-suppressing effect fades with them. Hunger signals that were being dampened typically return to something closer to how they felt before treatment, and for most people that means wanting to eat more than they did while on the medicine.

This isn't a sign that anything has gone wrong, and it doesn't mean the medicine has stopped "working" in some unusual way. It's the expected result of removing a medicine whose main effect is on appetite, which is why planning ahead for this change matters more than it might for other types of treatment.

Neither medicine leaves your system the moment you take your last dose. UK product information for both describes a half-life of roughly a week, meaning it typically takes several weeks after your final injection for drug levels to fall substantially. In practice, this means the return of appetite tends to be gradual over that first month rather than sudden, which gives you a window to put support in place before hunger fully returns to its pre-treatment level.

What the trial evidence shows about weight regain

Much of what's known about stopping GLP-1/GIP treatment comes from a clinical trial of tirzepatide (the active ingredient in Mounjaro) called SURMOUNT-4, published in JAMA. In that trial, everyone took tirzepatide for an initial 36 weeks, then one group continued on the medicine while another switched to a placebo (a dummy treatment with no active drug) for a further year.

Over that year, the group who continued tirzepatide lost a further 6 to 7% of their body weight on top of what they'd already lost. The group who switched to placebo, in contrast, regained an average of 14% of their lost weight. A later analysis of that same placebo group found that around 82% of participants regained at least a quarter of the weight they had lost within the year after stopping, while a smaller number, roughly 1 in 10, regained all of it.

These figures come from a trial of tirzepatide specifically, but the underlying mechanism, appetite returning once the medicine is cleared, applies across this class of medicines, which is why similar patterns are widely reported anecdotally among people stopping semaglutide-based treatments like Wegovy too. Individual experience varies considerably, and these averages don't predict what will happen for any one person.

The health effects of regain, not just the number on the scale

The same trial analysis looked beyond the scale at measures like waist circumference, blood pressure, cholesterol and blood sugar. It found that as weight regain increased, these measures tended to worsen alongside it, broadly reversing some of the improvements seen during treatment. People who regained less than a quarter of their lost weight generally kept more of those benefits than people who regained more.

This matters because the value of weight loss treatment isn't only about the number on the scale. For many people, the point of treatment is the knock-on improvement to blood pressure, cholesterol, blood sugar control or joint strain, and significant regain can mean some of that benefit is lost too, not just the weight itself.

NICE guidance on support after stopping

NICE, the UK body that sets clinical guidance for the NHS, has published a quality standard on maintaining weight after treatment with weight-management medicines. It recommends that anyone stopping a weight-management medicine, or finishing a structured behavioural programme, through the NHS should be offered follow-up support, such as regular check-ins and a personal action plan, for a minimum of 12 months.

That standard also points towards practical support beyond appointments: peer groups such as walking or activity groups, NHS resources like the Better Health platform, and access to dietitians where available. The aim is to help people hold on to the habits built during treatment rather than leaving them to manage the transition alone.

It's worth being clear that this standard applies to NHS-provided treatment. Most people in the UK taking medicines like Mounjaro or Wegovy pay for them privately, so this specific NHS follow-up pathway may not automatically apply. If you're a private patient, it's reasonable to ask your provider directly what support, if any, is available once treatment ends.

Options other than stopping completely

Stopping doesn't have to be all-or-nothing. For some people, moving to a lower maintenance dose, rather than stopping altogether, helps keep weight more stable while still allowing less frequent dosing or a lower cost, provided this is agreed and monitored with a prescriber rather than self-adjusted.

Lifestyle habits built during treatment, around portion sizes, meal patterns, activity levels and how you respond to hunger cues, tend to matter more once the medicine's effect on appetite fades. Many people find that the habits they practised while on treatment are what carries weight maintenance forward, rather than any single change made after stopping.

There's no fixed length of treatment that's right for everyone. Some people use these medicines for a defined period before stopping; others continue for longer under ongoing review. The right approach depends on your individual goals, how you've responded to treatment, any side effects, and a conversation with your prescriber about what happens next.

Whichever path you take, it helps to put support in place before you stop rather than after. That might mean arranging a follow-up appointment for a set point after your last dose, writing down the eating habits and routines that worked well during treatment so they're easier to keep going, or simply knowing in advance who to contact if hunger or weight starts climbing faster than you expected.

When to speak to your prescriber before stopping

A few situations are worth raising with your prescriber before you stop, rather than stopping first and dealing with the consequences afterwards. These include stopping because of cost pressures, since there may be alternative doses, schedules, or NHS pathways worth exploring first; planning a pregnancy, since these medicines aren't used in pregnancy and timing matters; and noticing old patterns around food or eating returning quickly, since early support tends to be more effective than waiting.

If you've already stopped and are finding appetite or weight regain difficult to manage, it's still worth getting in touch rather than assuming the window for support has passed. A prescriber can talk through whether restarting, adjusting your approach, or additional support makes sense for your situation.

Whatever stage you're at, the common thread is the same: this is a decision best made with input from someone who knows your treatment history, not one to navigate alone based on general advice, including this article.